Evidence map›Paper›PMID 35858896›Full record

ReviewJournal of nanobiotechnology2022

Recent advances in smart nanoplatforms for tumor non-interventional embolization therapy.

Heng Dong, Dongliang Yang, Yanling Hu, Xuejiao Song

Open access · goldAbstract readReview
In one paragraph

Review in Journal of nanobiotechnology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.6field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 24 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Heng DongNanjing Stomatological Hospital, Medical School of Nanjing University Jiangsu, 30 Zhongyang Road, 210008, Nanjing, China.ORCID http://orcid.org/0000-0002-2537-7950
Dongliang YangSchool of Physical and Mathematical Sciences, Nanjing Tech University (NanjingTech), 30 South Puzhu Road, 211816, Nanjing, China.
Yanling HuSchool of Physical and Mathematical Sciences, Nanjing Tech University (NanjingTech), 30 South Puzhu Road, 211816, Nanjing, China. huyanling@njpi.edu.cn.
Xuejiao SongSchool of Physical and Mathematical Sciences, Nanjing Tech University (NanjingTech), 30 South Puzhu Road, 211816, Nanjing, China. xjsong@njtech.edu.cn.
Nanjing Tech University · CNNanjing University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Tumor embolization therapy has attracted great attention due to its high efficiency in inhibiting tumor growth by cutting off tumor nutrition and oxygen supply by the embolic agent. Although transcatheter arterial embolization (TAE) is the mainstream technique in the clinic, there are still some limitations to be considered, especially the existence of high risks and complications. Recently, nanomaterials have drawn wide attention in disease diagnosis, drug delivery, and new types of therapies, such as photothermal therapy and photodynamic therapy, owing to their unique optical, thermal, convertible and in vivo transport properties. Furthermore, the utilization of nanoplatforms in tumor non-interventional embolization therapy has attracted the attention of researchers. Herein, the recent advances in this area are summarized in this review, which revealed three different types of nanoparticle strategies: (1) nanoparticles with active targeting effects or stimuli responsiveness (ultrasound and photothermal) for the safe delivery and responsive release of thrombin; (2) tumor microenvironment (copper and phosphate, acidity and GSH/H

Indexed as

Embolization, TherapeuticNanoparticlesNeoplasmsHumansHydrogen PeroxideTumor MicroenvironmentHydrogen PeroxideCombination therapySmart nanoplatformsthrombusTumor non-interventional embolization therapyTumor vascular occlusion

Identifiers

PMID35858896
PMCPMC9301833
OpenAlexW4286008555

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.